Salugen Announces the Publication of the T.R.I.M. Study Where Study Participants Taking GenoTrim Had an Average Weight Loss of 17.15 Pounds and 10.17

San Diego, CA (PRWEB) June 5, 2007 -- Salugen (www.salugen.com), a leading personalized health and wellness company, announces study results from the T.R.I.M. Study (Treatment Results in Improved Metrics of Weight Loss) published in the peer-reviewed medical journal, Advances in Therapy examining the effects of GenoTrim, the DNA-customized nutritional solution for weight management (www.GenoTrim.com).

In this published study entitled, "Reward Deficiency Syndrome in Obesity: A Preliminary Cross-Sectional Trial with a GenoTrim Variant", investigators studied 24 subjects taking a version of GenoTrim. In the T.R.I.M. study, 83% of subjects lost weight and the average weight loss was 17.15 pounds.

"Seventeen years ago, I published landmark research in the Journal of the American Medical Association suggesting that another prevalent healthcare condition, namely alcoholism, which had been traditionally characterized in behavioral terms like weight problems, also had a hereditary or genetic component. Like alcoholism, weight problems are due, in part, to certain genetic predispositions; and by the body engaging in behavior to overcome these deficiencies, the host may engage in behaviors that are individually unhealthy or detrimental," states Dr. Kenneth Blum, Professor in Department of Physiology & Pharmacology at Wake Forest University School of Medicine. Dr. Blum is also Chief Scientific Officer for Salugen, Inc. Dr. Blum goes onto say, "In GenoTrim, we have combined specific nutrients to influence various functions or paths that are affected by dopaminergic activity or what I have termed Reward Deficiency Syndrome, including sleep, mood, energy, stress, and immune and hormonal function. When these paths are considered, a multidisciplinary approach can be pursued that appropriately targets underlying factors that influence weight."

In the T.R.I.M. study, correlations were seen suggesting that 2 major paths to weight loss originate with stress reduction. The first leads from reduction in stress through improved sleep, heightened energy, and positive focus to improved performance. The second passes from reduction in stress through reduced appetite, reduced weight, and decreased inches to well-being.

Examination of the data indicates a number of very interesting correlations (both negative and positive): Stress is negatively correlated with sleep (r = -0.49), whereby when stress is high sleep is low; stress is positively correlated with appetite (r = 0.42), whereby when stress is high appetite is high; stress is negatively correlated with energy (r = _0.24) whereby when stress is high energy is low; sleep is positively correlated with energy (r = 0.44), whereby when sleep is high energy is high; stress is negatively correlated with wellbeing (r = -0.36), when stress is high wellbeing is low; sleep is positively correlated with performance (r = 0.40), whereby when sleep is high performance is high; appetite is negatively correlated with focus (r = -0.30), whereby when appetite is high focus is low; appetite is positively correlated with weight (r = 0.21), whereby when appetite is high weight is high.

Findings from this open-label, cross-sectional study revealed a number of beneficial effects of the GenoTrim formula. The duration of benefit ranged from 8 days to 12 months. It is interesting to note that after only 8 days of use, subjects experienced a reduction in stress, enhanced well-being, a decrease in sugar cravings, and a reduction in appetite. Although 1 individual experienced an increase in body weight (3 lb over 5 mo), 83% of subjects achieved weight reduction by the time the study ended. Of 24 individuals who responded, 96% reported a greater feeling of well-being, 83% achieved weight reduction, 79% reported a significant suppression of appetite, 75% described a reduced craving for sugar, 75% reported a reduction in stress, 70% achieved loss of inches, 54% reported increased energy, 42% described positive sleep patterns, 25% related an enhanced focus, and 21% reported enhanced performance.

About GenoTrim:
GenoTrim is a DNA-customized nutritional solution for weight management. Based upon an analysis of five important genes effecting weight, GenoTrim ingredients and dosages are genetically-guided to address the underlying genetic factors involved in hormones and metabolism that Harvard Medical Experts suggest influence 70% to 80% of overweight cases. By addressing genetic factors that make individuals prone to weight problems, GenoTrim has demonstrated in studies to help reduce weight, appetite, sugar cravings, snacking, and late-night eating, as well as help support improved sleep, mood, and energy levels which results in sustainable weight loss. GenoTrim will be available in the United States through DNA Services of America (www.dnasoa.com) later in 2007. For more information on GenoTrim, please visit www.genotrim.com.

About Salugen:
Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit http://www.salugen.com.

###